This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John J. Kneisel, MD

AMA Arch Surg. 1968;96(3):442-449.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ACUTE pancreatitis is clinically unpredictable and terminates fatally in enough instances to warrant careful evaluation of any possible therapy. In the more severe disease, activation of its own enzymes results in progression of the pancreatic pathological process. For this reason, a further investigation of a proteinase inhibitor (Trasylol [Germany]) is reported here after its clinical use by the intravenous route. The comparison of a large series of closely matched cases will ultimately provide firm assessment of the enzyme inhibitor. The present study measures several appropriate phenomena in a group of generally comparable cases of acute pancreatitis treated conventionally, with or without the addition of intravenous proteinase inhibitor.

Method

The test enzyme inhibitor was offered to all attending physicians for use in moderately severe or severe acute pancreatitis. Temperatures which reached 100 F (37.8 C) were considered indicative of moderately severe disease while marked hemoconcentration, moderate shock, and toxic or central . . . [Full Text PDF of this Article]

Author Affiliations
New Haven, Conn

From the Yale University School of Medicine, New Haven, Conn. Dr. Kneisel is now with the University of Connecticut School of Medicine, Hartford.

Footnotes
Submitted for publication June 1, 1967.

Reprint requests to 2 Holcomb St, Hartford, Conn 06112.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?